Phase 1 trial will include 16 patients ages 60 to 85 years who have early, symptomatic Alzheimer disease but are otherwise in good health
In randomized, double-blind trial, no difference seen in scores for agitated behaviors at 12 weeks with mirtazapine versus placebo
Does not improve primary outcome, but did improve performance on certain cognitive tasks in those with epileptiform activity
Overall, 92.2, 91.0, and 85.5 percent of Medicare beneficiaries with ADRDs, Alzheimer disease, and MCI met at least one of the exclusion criteria
Risk for AD increased for parents of individuals with ADHD; associations attenuated with decreasing genetic relatedness
Individual doctors can prescribe Aduhelm, but patients would have to go elsewhere to receive the drug via infusion
Taking up reading, puzzles, and games even in one's 80s may provide cognitive protection
CMS says a final decision on coverage is not likely until next spring
Request follows reports that Biogen and the FDA held off-the-books meetings before the drug's approval that may have violated FDA protocol
Major changes to prescribing instructions are rare, especially so soon after approval; change could curb the drug's use